Our antibodies are used in research studies worldwide Keep reading our latest Research Roundup! The following three studies have successfully utilized Atlas Antibodies products in stem cell research.
1) SVCT2 promotes neural stem/progenitor cells migration by activating CDC42 after ischemic stroke
Ischemic stroke remains a leading cause of death and long-term disability through an irreversible “ischemic cascade,” including disrupted energy balance related to variations in oxygen and glucose concentrations and the depletion of cellular energy stores, and the release of inflammatory mediators. Increasing evidence has demonstrated that activating endogenous neural stem progenitor cells (NSPCs) can pave the way for the augmented long-term experimental recovery of injured brain tissue.
This study indicates that the sodium-vitamin C cotransporter 2 (SLC23A2 or SVCT2), is mainly expressed in the brain and located in NSPC of the inner and outer subventricular zone, promotes the migration of NPSCs through CDC42 activation to facilitate F-actin assembling, which importantly enlarges the therapeutic scope of ascorbic acid and the role of SVCT2 in NSPCs migration after brain injury.
The immunofluorescent staining on mouse brain sections was done using Atlas Antibodies’ polyclonal anti-SLC23A2 antibody (HPA052825)
Yang et al. SVCT2 promotes neural stem/progenitor cells migration through activating CDC42 after ischemic stroke. Front Cell Neurosci, 2019; 13:429.